Complete Filing Data
Monopar Therapeutics reported Stockholders Equity of $137.83 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Monopar Therapeutics did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M | -$3.2M | -$16.6M | -$1.2M |
| Research And Development Expense | $9.9M | $13.0M | $5.6M | $7.6M | $6.5M | $4.1M | $2.0M | $1.8M | $935.3K | $280.4K |
| Operating Income Loss | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M | -$6.5M | -$4.3M | -$3.3M | -$16.6M | -$1.2M |
| Operating Expenses | $16.7M | $16.2M | $8.8M | $10.5M | $9.1M | $6.5M | $4.3M | $3.3M | $16.6M | $1.2M |
| General And Administrative Expense | $6.8M | $3.2M | $3.2M | $2.9M | $2.6M | $2.4M | $2.4M | $1.6M | $1.2M | $912.5K |
| Comprehensive Income Net Of Tax | -$13.6M | -$15.5M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M | -$3.2M | -$16.6M | |
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -$4.2K | $1.6K | -$17.3K | -$2.9K | $4.7K | $3.1K | -$8.6K | -$2.4K | $0.00 | |
| Interest Income Expense Net | $429.0K | $21.2K | $24.0K | $81.9K | $98.9K | $103.2K | $48.3K | $7.2K | ||
| Other Comprehensive Income Loss Net Of Tax | $12.1K | $4.7K | $3.1K | -$8.6K | -$2.4K | |||||
| Revenues | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $95.4K | $50.1K | -$23.1K | $12.1K | ||||||
| Research And Development In Process | $0.00 | $14.5M | $0.00 | |||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $99.6K | $48.5K | -$5.8K | $15.0K | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.3M | -$16.6M | ||||||||
| Deferred Income Tax Expense Benefit | -$71.6K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.4M | -$2.5M | -$2.6M | -$1.3M | -$1.7M | -$1.6M | -$2.0M | -$2.2M | -$2.4M | -$2.4M | -$2.8M | -$2.5M | -$2.5M | -$2.1M | -$1.9M | -$1.6M | -$1.4M | -$1.1M | -$736.1K | -$905.7K | -$1.4M | -$890.5K | -$640.2K | -$640.2K | -$876.3K | -$14.9M | -$591.4K | -$372.9K |
| Research And Development Expense | $2.6M | $1.7M | $1.6M | $984.3K | $1.1M | $966.1K | $1.3M | $1.6M | $1.7M | $1.7M | $2.1M | $1.7M | $1.8M | $1.5M | $1.2M | $1.3M | $832.5K | $344.4K | $219.8K | $329.3K | $835.6K | $303.7K | $303.7K | $457.1K | $180.7K | $311.6K | $133.7K | |
| Operating Income Loss | -$4.1M | -$3.2M | -$3.2M | -$1.6M | -$1.8M | -$1.7M | -$2.1M | -$2.3M | -$2.5M | -$2.4M | -$2.8M | -$2.5M | -$2.5M | -$2.1M | -$1.9M | -$1.6M | -$1.5M | -$1.1M | -$759.4K | -$932.1K | -$1.4M | -$667.5K | -$667.5K | -$897.3K | -$14.9M | -$595.0K | -$373.8K | |
| Operating Expenses | $4.1M | $3.2M | $3.2M | $1.6M | $1.8M | $1.7M | $2.1M | $2.3M | $2.5M | $2.4M | $2.8M | $2.5M | $2.5M | $2.1M | $1.9M | $1.6M | $1.5M | $1.1M | $759.4K | $932.1K | $1.4M | $667.5K | $667.5K | $897.3K | $14.9M | $595.0K | $373.8K | |
| General And Administrative Expense | $1.5M | $1.5M | $1.6M | $590.6K | $657.8K | $757.3K | $749.5K | $733.5K | $871.7K | $675.1K | $684.9K | $779.3K | $631.7K | $616.0K | $687.9K | $392.1K | $631.6K | $791.6K | $539.6K | $602.8K | $571.7K | $363.8K | $363.8K | $440.1K | $215.2K | $283.4K | $240.1K | |
| Comprehensive Income Net Of Tax | -$3.5M | -$2.4M | -$2.6M | -$1.3M | -$1.7M | -$1.6M | -$2.0M | -$2.2M | -$2.4M | -$2.4M | -$2.7M | -$584.00 | -$2.5M | -$57.00 | -$1.9M | -$1.6M | -$1.4M | -$1.1M | -$744.8K | -$904.6K | -$1.4M | -$641.0K | -$641.0K | -$876.3K | -$14.9M | -$591.4K | ||
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -$116.00 | -$3.5K | $1.2K | $5.2K | $1.6K | -$835.00 | $6.9K | -$4.4K | -$10.8K | $25.5K | $21.2K | -$584.00 | $9.00 | -$55.00 | $2.8K | $1.5K | $3.5K | -$4.0K | -$8.7K | $1.1K | -$2.1K | -$806.00 | -$806.00 | $0.00 | $0.00 | $0.00 | ||
| Interest Income Expense Net | $73.5K | $82.2K | $112.3K | $128.2K | $90.5K | $7.7K | $417.00 | $464.00 | $577.00 | $12.2K | $10.7K | $8.5K | $18.3K | $45.1K | $23.4K | $26.4K | $31.1K | $27.3K | $27.3K | $20.9K | $20.6K | $3.5K | $924.00 | |||||
| Other Comprehensive Income Loss Net Of Tax | $21.2K | -$584.00 | $9.00 | -$57.00 | $2.8K | $1.5K | $3.5K | -$4.0K | -$8.7K | $1.1K | -$2.1K | -$11.00 | -$806.00 | -$1.6K | ||||||||||||||
| Revenues | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$65.9K | $99.4K | -$57.8K | -$19.2K | $4.0K | $18.4K | -$3.3K | -$24.6K | $22.8K | $25.5K | $21.2K | -$584.00 | -$1.9M | |||||||||||||||
| Research And Development In Process | $0.00 | $14.5M | ||||||||||||||||||||||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$65.8K | $102.8K | $346.00 | -$24.4K | $2.4K | $19.2K | -$10.2K | -$20.2K | $33.6K | $0.00 | $0.00 | |||||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | ||||||||||||||||||||||||||||
| Deferred Income Tax Expense Benefit |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M | $15.7M | $12.6M | $6.9M | $9.6M | $2.8M | $2.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $16.7M | $13.2M | $6.9M | $9.8M | $2.9M | $2.8M | |||||
| Cash And Cash Equivalents At Carrying Value | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M | $16.7M | $13.2M | $6.9M | $9.0M | $2.1M | |
| Retained Earnings Accumulated Deficit | -$89.5M | -$75.8M | -$60.2M | -$51.8M | -$41.3M | -$32.2M | -$25.9M | -$21.7M | -$18.4M | -$1.9M | |
| Liabilities And Stockholders Equity | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M | $16.9M | $13.4M | $7.3M | $9.9M | $2.9M | |
| Common Stock Value | $6.7K | $6.1K | $3.0K | $12.9K | $12.6K | $11.5K | $10.6K | $9.3K | $9.3K | $0.00 | |
| Assets Current | $140.5M | $60.3M | $7.3M | $13.2M | $20.5M | $16.8M | $13.2M | $7.3M | $9.1M | $2.1M | |
| Assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M | $16.9M | $13.4M | $7.3M | $9.9M | $2.9M | |
| Accounts Payable And Accrued Liabilities Current | $2.7M | $2.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724.2K | $399.6K | $311.9K | $64.5K | |
| Liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724.2K | $399.6K | $311.9K | $64.5K | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $131.4K | $36.0K | -$14.1K | $8.9K | -$3.2K | -$7.9K | -$11.0K | -$2.4K | $0.00 | ||
| Liabilities Current | $2.7M | $5.3M | $1.8M | $3.1M | $1.6M | $724.2K | $399.6K | $311.9K | $64.5K | ||
| Cash And Cash Equivalents Period Increase Decrease | $3.5M | $6.3M | -$2.9M | $6.9M | $67.9K | ||||||
| Prepaid Expense And Other Assets | $14.5K | $149.3K | $22.6K | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M | ||||||
| Other Assets Current | $63.7K | $78.9K | $66.4K | $46.0K | $217.7K | $62.7K | $15.7K | ||||
| Operating Lease Right Of Use Asset | $254.9K | $0.00 | $12.6K | $61.2K | $0.00 | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $16.0M | $38.6M | -$920.1K | -$12.1M | $3.6M | ||||||
| Cash Acquired From Acquisition | $0.00 | $4.8M | $0.00 | ||||||||
| Restricted Cash | $0.00 | $800.0K | $800.4K | ||||||||
| Operating Lease Liability Noncurrent | $154.9K | $0.00 | $0.00 | $8.4K | $0.00 | ||||||
| Liabilities Noncurrent | $0.00 | $0.00 | $0.00 | ||||||||
| Investments | $78.6M | $14.4M | $0.00 | $4.9M | $0.00 | ||||||
| Additional Paid In Capital Common Stock | $227.2M | $130.8M | $65.8M | $61.9M | |||||||
| Deferred Offering Costs | $10.3K | $344.9K | |||||||||
| Other Assets Noncurrent | $0.00 | $68.9K | $122.4K | $65.7K | |||||||
| Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount | |||||||||||
| Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $141.6M | $52.2M | $53.6M | $4.9M | $6.1M | $7.5M | $6.6M | $7.8M | $8.9M | $12.5M | $14.5M | $17.0M | $21.3M | $23.4M | $25.1M | $17.5M | $12.2M | $12.4M | $4.6M | $5.1M | $5.8M | $7.6M | $8.1M | $8.9M | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.7M | $8.2M | $14.3M | $16.5M | $17.8M | $20.3M | $22.3M | $24.3M | $25.7M | $18.0M | $12.5M | $12.6M | $4.5M | $5.1M | $5.9M | $7.6M | $8.2M | $9.0M | $10.6M | $4.3M | $3.6M | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $127.7M | $39.5M | $39.7M | $6.0M | $6.1M | $7.8M | $5.5M | $7.2M | $5.7M | $14.3M | $16.5M | $17.8M | $22.3M | $24.3M | $25.7M | $18.0M | $12.5M | $12.6M | $4.5M | $5.1M | $5.9M | $7.6M | $7.4M | $8.2M | |||||||
| Retained Earnings Accumulated Deficit | -$84.3M | -$80.9M | -$78.4M | -$64.9M | -$63.6M | -$61.8M | -$58.4M | -$56.4M | -$54.2M | -$48.9M | -$46.5M | -$43.7M | -$38.6M | -$36.1M | -$34.1M | -$30.1M | -$28.4M | -$27.0M | -$24.7M | -$3.5K | -$23.0M | -$20.8M | -$20.1M | -$19.3M | |||||||
| Liabilities And Stockholders Equity | $144.2M | $53.9M | $55.1M | $6.1M | $7.2M | $8.9M | $8.6M | $10.3M | $11.8M | $14.4M | $16.7M | $18.1M | $22.5M | $24.5M | $25.9M | $18.2M | $12.8M | $12.8M | $5.1M | $5.6M | $6.4M | $7.9M | $8.4M | $9.1M | |||||||
| Common Stock Value | $6.7K | $6.1K | $6.1K | $3.5K | $17.6K | $17.5K | $14.2K | $13.9K | $13.2K | $12.9K | $12.7K | $12.6K | $12.6K | $12.6K | $12.6K | $11.5K | $10.7K | $10.6K | $9.3K | $9.3K | $9.3K | $9.3K | $9.3K | $9.3K | |||||||
| Assets Current | $144.1M | $53.7M | $55.1M | $6.1M | $7.2M | $8.9M | $8.6M | $10.3M | $11.8M | $14.4M | $16.7M | $18.0M | $22.4M | $24.4M | $25.8M | $18.1M | $12.7M | $12.7M | $5.1M | $5.6M | $6.4M | $7.9M | $7.6M | $8.3M | |||||||
| Assets | $144.2M | $53.9M | $55.1M | $6.1M | $7.2M | $8.9M | $8.6M | $10.3M | $11.8M | $14.4M | $16.7M | $18.1M | $22.5M | $24.5M | $25.9M | $18.2M | $12.8M | $12.8M | $5.1M | $5.6M | $6.4M | $7.9M | $8.4M | $9.1M | |||||||
| Accounts Payable And Accrued Liabilities Current | $2.6M | $1.6M | $1.5M | $1.1M | $1.1M | $1.4M | $2.0M | $2.5M | $2.9M | $1.9M | $2.2M | $1.1M | $1.2M | $1.1M | $806.3K | $542.1K | $525.7K | $443.5K | $483.7K | $468.3K | $580.0K | $311.9K | $323.1K | $290.6K | |||||||
| Liabilities | $2.6M | $1.7M | $1.5M | $1.1M | $1.1M | $1.4M | $2.0M | $2.5M | $2.9M | $1.9M | $2.2M | $1.1M | $1.2M | $1.1M | $664.5K | $648.1K | $443.5K | $483.7K | $468.3K | $580.0K | $311.9K | $323.1K | $290.6K | ||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $11.7K | $77.6K | -$21.8K | -$11.0K | $8.3K | $4.2K | $3.9K | $7.2K | $31.8K | $43.0K | $17.5K | -$3.7K | -$5.1K | -$5.2K | -$5.1K | -$10.0K | -$11.6K | -$15.0K | -$12.2K | -$23.9M | -$4.5K | -$2.4K | -$1.6K | ||||||||
| Liabilities Current | $2.6M | $1.6M | $2.0M | $2.5M | $2.9M | $1.9M | $2.2M | $1.1M | $806.3K | $1.2M | $609.8K | $573.1K | $443.5K | $483.7K | $468.3K | $580.0K | $311.9K | $323.1K | $290.6K | ||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | -$2.5M | $9.0M | -$621.6K | -$1.0M | -$808.8K | $678.5K | |||||||||||||||||||||||||
| Prepaid Expense And Other Assets | $114.6K | $62.7K | $104.6K | $183.4K | $124.2K | $15.7K | $84.9K | $94.1K | $101.6K | $269.5K | $228.1K | $175.1K | |||||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $127.7M | $39.5M | $39.7M | $6.0M | $6.1M | $7.8M | $5.5M | $7.2M | $5.7M | $14.3M | $16.5M | ||||||||||||||||||||
| Other Assets Current | $414.8K | $497.3K | $523.6K | $49.6K | $61.0K | $119.0K | $73.2K | $109.9K | $106.8K | $55.7K | $189.2K | $193.6K | $106.8K | $95.6K | |||||||||||||||||
| Operating Lease Right Of Use Asset | $106.7K | $118.2K | $9.1K | $0.00 | $0.00 | $0.00 | $25.1K | $37.3K | $49.4K | $72.9K | $84.4K | $53.7K | $0.00 | ||||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$6.1M | $541.5K | -$2.5M | -$2.5M | |||||||||||||||||||||||||||
| Cash Acquired From Acquisition | |||||||||||||||||||||||||||||||
| Restricted Cash | $0.00 | $800.0K | $800.0K | ||||||||||||||||||||||||||||
| Operating Lease Liability Noncurrent | $70.9K | $80.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.9K | $33.1K | $25.3K | $0.00 | $0.00 | $0.00 | ||||||||||||||||||
| Liabilities Noncurrent | $54.6K | $75.0K | $0.00 | ||||||||||||||||||||||||||||
| Investments | $16.0M | $13.7M | $14.8M | $998.8K | $985.7K | $3.0M | $3.0M | $6.0M | |||||||||||||||||||||||
| Additional Paid In Capital Common Stock | $225.8M | $133.0M | $132.0M | $69.8M | $69.6M | $69.3M | $65.0M | $64.3M | |||||||||||||||||||||||
| Deferred Offering Costs | $529.2K | $371.1K | $371.1K | ||||||||||||||||||||||||||||
| Other Assets Noncurrent | $68.9K | $68.9K | $68.9K | $68.9K | $73.1K | $122.4K | |||||||||||||||||||||||||
| Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||||||||||
| Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount | -$16.8K | -$10.7K | -$29.7K | -$16.7K | -$10.0K | -$24.0K | -$21.5K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $4.8M | $1.1M | $1.9M | $1.6M | $1.5M | $1.3M | $1.0M | $529.3K | $305.2K | $0.00 |
| Net Cash Provided By Used In Operating Activities | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M | -$4.7M | -$3.0M | -$2.7M | -$2.6M | -$1.2M |
| Net Cash Provided By Used In Financing Activities | $91.6M | $59.3M | $2.0M | $32.9K | $10.9M | $8.2M | $9.3M | -$206.3K | $9.5M | $1.3M |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $388.2K | $506.8K | -$1.3M | $1.5M | $447.6K | $243.5K | $87.7K | $247.4K | -$9.3K | |
| Proceeds From Issuance Of Common Stock | $0.00 | $4.2M | $2.1M | $109.3K | $8.2M | $0.00 | $0.00 | $4.7M | $0.00 | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $3.8K | -$9.1K | $3.8K | $126.8K | -$298.00 | |||||
| Proceeds From Stock Options Exercised | $565.2K | $84.00 | $0.00 | $169.00 | $17.5K | $0.00 | $110.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations | -$3.5K | $4.6K | $3.3K | |||||||
| Increase Decrease In Other Current Assets | -$15.4K | $12.8K | $20.4K | -$171.8K | -$86.2K | |||||
| Increase Decrease In Deferred Charges | ||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.3K | -$8.6K | -$2.4K | $0.00 | ||||||
| Net Cash Provided By Used In Investing Activities | -$63.5M | -$14.3M | $4.9M | -$4.9M | $0.00 | |||||
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | $23.7M | $985.7K | $12.8M | $0.00 | ||||||
| Payments To Acquire Short Term Investments | $87.2M | $15.3M | $7.9M | $4.9M | ||||||
| Payments Related To Tax Withholding For Share Based Compensation | $1.1M | $104.2K | $47.0K | $76.6K | ||||||
| Increase Decrease In Operating Lease Right Of Use Assets And Liabilities | $9.4K | -$4.2K | $0.00 | $4.2K | ||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $97.3K | $494.00 | -$16.8K | -$3.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $1.4M | $328.7K | $476.2K | $357.3K | $499.8K | $392.1K | $357.6K | $368.2K | $283.7K | $367.4K | $338.5K | $243.0K | $257.6K | $233.8K | $233.0K | $93.2K | $88.6K | $114.5K | $0.00 |
| Net Cash Provided By Used In Operating Activities | -$5.7M | -$1.7M | -$2.3M | -$2.5M | -$1.9M | -$1.1M | -$996.0K | -$808.8K | -$311.5K | ||||||||||
| Net Cash Provided By Used In Financing Activities | -$115.7K | $3.2M | $804.8K | -$16.7K | $10.9M | $508.0K | -$13.9K | $0.00 | $990.0K | ||||||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$771.0K | -$311.2K | -$251.9K | -$532.3K | -$370.4K | -$331.1K | $167.9K | -$21.3K | $53.9K | ||||||||||
| Proceeds From Issuance Of Common Stock | $0.00 | $3.2M | $821.6K | $10.9M | $508.0K | $0.00 | $0.00 | $990.0K | |||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $51.9K | $42.1K | $21.4K | $25.8K | -$7.6K | ||||||||||||||
| Proceeds From Stock Options Exercised | $15.4K | $0.00 | $0.00 | $17.5K | $0.00 | ||||||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations | -$10.8K | -$659.00 | $2.8K | -$4.0K | -$1.9K | $0.00 | |||||||||||||
| Increase Decrease In Other Current Assets | $621.5K | $35.9K | $60.8K | $24.1K | $51.9K | ||||||||||||||
| Increase Decrease In Deferred Charges | $18.1K | $13.9K | $0.00 | ||||||||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | |||||||||||||||||||
| Net Cash Provided By Used In Investing Activities | -$325.8K | -$983.3K | -$983.4K | $0.00 | |||||||||||||||
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | $1.6M | $0.00 | $2.0M | $0.00 | |||||||||||||||
| Payments To Acquire Short Term Investments | $1.9M | $983.3K | $3.0M | ||||||||||||||||
| Payments Related To Tax Withholding For Share Based Compensation | $131.1K | $10.7K | $16.8K | ||||||||||||||||
| Increase Decrease In Operating Lease Right Of Use Assets And Liabilities | $850.00 | -$4.2K | $0.00 | ||||||||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$54.00 | -$1.7K | -$10.8K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Share Outstanding Basic And Diluted | 12.5M | 11.0M | 9.3M | 9.3M | 8.8M | |||||
| Earnings Per Share Basic And Diluted | $-0.73 | $-0.58 | $-0.45 | $-0.35 | $-1.89 | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 6.7M | 6.1M | 3.0M | 12.9M | 12.6M | 11.5M | 10.6M | 9.3M | 9.3M | 0.00 |
| Common Stock Shares Issued | 6.7M | 6.1M | 3.0M | 12.9M | 12.6M | 11.5M | 10.6M | 9.3M | 9.3M | 0.00 |
| Common Stock Shares Authorized | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M |
| Weighted Average Number Of Shares Outstanding Basic | 7.4M | 3.8M | 2.8M | 12.7M | 12.5M | |||||
| Earnings Per Share Basic | $-1.85 | $-4.11 | $-3.04 | $-0.83 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Share Outstanding Basic And Diluted | 12.6M | 12.6M | 12.6M | 12.1M | 11.1M | 10.6M | 10.6M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 8.9M | 8.6M | 8.3M | |||||||||||
| Earnings Per Share Basic And Diluted | $-0.19 | $-0.20 | $-0.17 | $-0.16 | $-0.15 | $-0.14 | $-0.10 | $-0.08 | $-0.10 | $-0.15 | $-0.07 | $-0.07 | $-0.09 | $-1.68 | $-0.07 | $-0.04 | |||||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 6.7M | 6.1M | 6.1M | 3.5M | 17.6M | 17.5M | 14.2M | 13.9M | 13.2M | 12.9M | 12.7M | 12.6M | 12.6M | 12.6M | 12.6M | 11.5M | 10.7M | 10.6M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | |||
| Common Stock Shares Issued | 6.7M | 6.1M | 6.1M | 3.5M | 17.6M | 17.5M | 14.2M | 13.9M | 13.2M | 12.9M | 12.7M | 12.6M | 12.6M | 12.6M | 12.6M | 11.5M | 10.7M | 10.6M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | |||
| Common Stock Shares Authorized | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | |||
| Weighted Average Number Of Shares Outstanding Basic | 7.1M | 7.0M | 7.0M | 3.5M | 3.5M | 3.2M | 2.8M | 13.4M | 13.1M | 12.8M | 12.6M | ||||||||||||||||
| Earnings Per Share Basic | $-0.48 | $-0.35 | $-0.38 | $-0.37 | $-0.49 | $-0.51 | $-0.69 | $-0.16 | $-0.19 | $-0.19 | $-0.22 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $60.2M | $47.9M | $38.5M | $28.6M | $28.0M | $4.7M | ||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.8M | $1.1M | $1.9M | $1.6M | ||||||
| Stock Issued During Period Value New Issues | $4.6M | $2.1M | $87.3K | $8.8M | $4.7M | |||||
| Stock Issued During Period Value Stock Options Exercised | $565.2K | $84.00 | $0.00 | $169.00 | $17.5K | $110.0K | $0.00 | |||
| Stock Issued During Period Value Restricted Stock Award Gross | $0.00 | $0.00 | $0.00 | |||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $98.2K | $87.6K | ||||||||
| Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units | -$76.6K | -$63.3K | $0.00 | |||||||
| Other Noncash Expense | $0.00 | $13.5M | $0.00 | |||||||
| Investment Income Interest | $3.0M | $404.0K | $429.0K | |||||||
| Stock Issued During Period Value Acquisitions | $0.00 | $18.3M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $63.1M | $61.9M | $61.4M | $61.0M | $60.7M | $59.9M | $59.5M | $59.2M | $47.5M | $40.6M | $39.4M | $29.3M | $29.1M | $28.8M | $28.3M | $28.2M | $28.2M | ||||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.1M | $1.3M | $1.4M | $199.1K | $334.4K | $328.7K | $474.1K | $473.3K | $476.2K | $390.7K | $357.3K | $499.8K | |||||||||||||
| Stock Issued During Period Value New Issues | $3.2M | $265.6K | $660.0K | $807.3K | $10.9M | $6.7M | $950.7K | $526.1K | |||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $213.00 | $4.7K | $15.4K | $84.00 | -$8.2K | $128.00 | $41.00 | $17.5K | |||||||||||||||||
| Stock Issued During Period Value Restricted Stock Award Gross | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $2.6K | $81.9K | $8.2K | $26.5K | $37.7K | $13.2K | $35.8K | ||||||||||||||||||
| Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units | -$16.8K | -$16.7K | $21.5K | $0.00 | |||||||||||||||||||||
| Other Noncash Expense | |||||||||||||||||||||||||
| Investment Income Interest | $655.5K | $780.8K | $596.8K | $99.3K | $73.5K | $82.2K | $112.3K | ||||||||||||||||||
| Stock Issued During Period Value Acquisitions |
Most recent annual filing with the SEC: March 27, 2026
Data sourced from SEC EDGAR public filings as of August 10, 2026.